Plasma kidney injury molecule-1 (p-KIM-1) levels and deterioration of kidney function over 16 years

Christina-Alexandra Schulz¹, Gunnar Engström¹, Jan Nilsson¹, Peter Almgren¹, Marinka Petkovic², Anders Christensson², Peter M. Nilsson³, Olle Melander¹ and Marju Orho-Melander¹

¹Department of Clinical Sciences, Lund University, Malmö, Sweden, ²Department of Nephrology, Lund University, Malmö, Sweden and ³Department of Medicine, Lund University, Malmö, Sweden

Correspondence and offprint requests to: Marju Orho-Melander; E-mail: marju.orho-melander@med.lu.se

ABSTRACT

Background. The kidney injury molecule-1 (KIM-1) has previously been associated with kidney function in rodents and humans. Yet its role as a predictive marker for future decline in kidney function has remained less clear.

Methods. At baseline (1991–1994), fasting plasma KIM-1 (p-KIM-1) was measured in 4739 participants of the population-based Malmö Diet and Cancer Study. Creatinine and cystatin C were used to calculate estimated glomerular filtration rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Collaboration 2012 creatinine–cystatin C equation at baseline and follow-up examination (2007–2012). Incident CKD was defined as an eGFR <60 mL/min/1.73 m² at follow-up.

Results. During a mean follow-up time of 16.6 years, high p-KIM-1 levels were associated with a greater decline in eGFR (quartile 1 –1.36 versus quartile 4 –1.54 mL/min/1.73 m²; P < 0.001). In multivariate analyses, the risk for incident CKD at the follow-up examination was higher among participants with baseline p-KIM-1 levels in the highest quartile [odds ratio [OR] 1.45 [95% confidence interval (CI) 1.10–1.92]] compared with those within the lowest quartile. The relative impact of baseline p-KIM-1 on incidence of CKD [OR 1.20 (95% CI 1.08–1.33) per 1 standard deviation (SD) increase in p-KIM-1] was comparable to those of age and systolic blood pressure (SBP) [OR 1.55 (95% CI 1.38–1.74) and OR 1.21 (95% CI 1.09–1.35) per 1 SD increase, respectively]. Adding p-KIM-1 to a conventional risk model resulted in significantly improved C-statistics (P = 0.04) and reclassified 9% of the individuals into the correct risk direction (continuous net reclassification improvement P = 0.02). Furthermore, the risk for hospitalization due to impaired renal function increased with increasing baseline p-KIM-1 [hazard ratio per 1 SD 1.43; (95% CI 1.18–1.74)] during a mean follow-up time of 19.2 years.

Conclusion. Our results show that p-KIM-1 predicts the future decline of eGFR and risk of CKD in healthy middle-aged participants. Whether p-KIM-1 can be used to prioritize preventive action that needs to be further investigated.

Keywords: CKD, eGFR, kidney function, KIM-1, TIM-1

INTRODUCTION

The kidney injury molecule-1 (KIM-1), also known as T-cell immunoglobulin and mucin-domain-containing molecule-1 (TIM-1), was first proposed to have a role in restoration after a kidney injury almost 2 decades ago, when KIM-1 was found to be markedly upregulated in the proximal tubular cells of rats after ischaemic injury [1]. More recently, chronic expression of KIM-1 in renal epithelial cells of transgenic mice was observed to lead to tubular interstitial fibrosis and inflammation, whereas mice with a truncated form of KIM-1 were protected from fibrosis [2]. In the first human study, high urinary KIM-1 (u-KIM-1) levels and extensive expression of this protein were detected in biopsies from the proximal tubule of patients with acute tubular necrosis [3]. Furthermore, higher u-KIM-1 has been associated with an enhanced decline of estimated glomerular filtration rate (eGFR) in patients with type 1 (T1D) [4] and type 2 diabetes (T2D) [5], whereas lower levels have been associated with regression of microalbuminuria in T1D [6]. However, studies evaluating u-KIM-1 as a marker of diabetic nephropathy have been inconclusive [4–8]. Moreover, u-KIM-1 did not add significant additional independent prognostic information in a prediction model with known risk factors in studies of T1D and T2D patients [4, 5], nor did it associate with CKD progression in a recent study of the Chronic Renal Insufficiency Cohort after controlling for urinary albumin:creatinine ratio and eGFR [9]. Another recent study reported that higher levels of u-KIM-1 were associated with lower eGFR and greater albuminuria in pooled cross-sectional multivariate analyses of five racially and ethnically diverse cohorts from Sweden and the USA [10].

©The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Concerning plasma KIM-1 (p-KIM-1), results from two controlled trials (ACCORD and VA NEPHRON-D) for early and advanced diabetic kidney disease (DKD) showed that higher p-KIM-1 levels were associated with a greater eGFR decline independent of known clinical risk factors [11]. Likewise, higher circulating levels were associated with deterioration of kidney function in T1D patients in the Joslin Kidney Study [12]. Importantly, that study investigated both u-KIM-1 and p-KIM-1 and observed that while high p-KIM-1 levels were associated with an increased risk of early progressive renal decline (independent of u-KIM-1), such an association was not seen for u-KIM-1 once p-KIM-1 was included in the analysis [12].

Taken together, although the current evidence indicates a role for KIM-1 in kidney function, the majority of studies so far have measured u-KIM-1 [3–6, 8–10] and less is known about the role of p-KIM-1 in kidney function [11–13]. Furthermore, whether p-KIM-1 may predict a longitudinal decline of kidney function in the generally healthy population has not been investigated. Therefore the aim of this study was to investigate if baseline levels of p-KIM-1 associate with longitudinal decline in kidney function, incidence of CKD or hospitalization due to renal impairment in the population-based Malmö Diet and Cancer Study (MDCS).

MATERIALS AND METHODS

MDCS

During 1991 and 1996, all men and women living in Malmö and born between 1923–45 and 1923–50, respectively, were invited to participate in the MDCS. The participation rate was 40.8% [14] and a detailed description of the cohort has been published elsewhere [15]. The study was approved by the ethical committee at Lund University (LU 51-90) and was carried out in accordance with the Helsinki Declaration. Written informed consent was provided by all the participants.

For this study, we included 4739 participants that provided fasting plasma samples at baseline from the MDCS Cardiovascular Cohort (MDCS-CC, N = 6103), which is a randomly selected subcohort of MDCS that underwent additional phenotyping between 1991 and 1994. Participants with missing data for smoking (n = 6), low-density lipoprotein (LDL) (n = 6), creatinine (n = 54) or cystatin C (n = 261) were excluded, leading to a study population of 4412 participants. Between 2007 and 2012, a total of 3734 MDCS-CC participants of those that were alive and had not emigrated from Sweden (n = 4924), attended a follow-up examination, which has been described previously [16]. Of these, 2799 participants had data on baseline p-KIM-1 and kidney function measures (Figure 1).

Clinical examination and assays

All participants underwent a physical examination and anthropometric measurements were obtained by trained nurses during the baseline examination. Systolic and diastolic blood pressure (SBP and DBP) were measured. Body mass index (BMI) was calculated as weight/height\(^2\) (kg/m\(^2\)). Questions concerning socio-economic status, lifestyle factors and medical history were assessed via a self-administered questionnaire [15].

Fasting blood samples were drawn and immediately frozen to −80°C and stored in a biobank [17]. Creatinine (µmol/L) was measured in plasma and analysed with the Jaffe method and traceable to the international standardization with isotope dilution mass spectrometry (IDMS). Cystatin C was measured using a particle-enhanced immunonephelometric assay (N Latex Cystatin; Dade Behring, Deerfield, IL, USA). The values of cystatin C were not standardized because they were analysed before the introduction of the world calibrator in 2010. The reference values for the method were 0.53–0.95 mg/L. Calculation of eGFR was done according to the previously reported Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine–cystatin C equation [18].

Following similar approaches as at baseline, anthropometric characteristics, SBP and DBP were measured during the follow-up examination (2007–12). Furthermore, fasting plasma glucose (mmol/L), creatinine (µmol/L) and cystatin C (mg/L) were measured using the same analytical methods as at baseline.

Baseline levels of p-KIM-1 were analysed by the Proximity Extension Assay technique using the Proseek Multiplex CVD66–96 reagents kit (Olink Bioscience, Uppsala, Sweden) at the Clinical Biomarkers Facility, Science for Life Laboratory, Uppsala. Oligonucleotide-labelled antibody probe pairs were allowed to bind to their respective targets present in the plasma sample and addition of a DNA polymerase led to an extension and joining of the two oligonucleotides and formation of a polymerase chain reaction (PCR) template. Universal primers were used to pre-amplify the DNA templates in parallel. Finally, the individual DNA sequences were detected and quantified using specific primers by a microfluidic real-time quantitative PCR chip (96.96, Dynamic Array IFC, Fluidigm Biomark). The chip was run with a Biomark HD instrument. The coefficient of variation for intra-assay variation (within-run) and interassay variation (between-run) for KIM-1 was 11% and 9%. Data analysis was performed by a preprocessing normalization procedure using Olink Wizard for GenEx (Multid Analyses, Göteborg, Sweden). All data are presented as normalized protein expression. General calibrator curves to calculate the approximate concentrations as well as technical information about the assays are available on the Olink homepage (http://www.olink.com).

Renal outcomes

CKD at follow-up examination was defined as an eGFR <60 mL/min/1.73 m\(^2\) based on one measurement of creatinine and cystatin C at the follow-up examination. We excluded all participants with prevalent CKD at baseline (n = 34) from the analysis of CKD incidence at follow-up.

We linked the MDCS-CC cohort to the Swedish patient register to obtain information on hospitalization due to impaired renal function (hiRF). The Swedish patient register covers all hospitalizations in Sweden since 1987 and hospital outpatient visits from 2001 onwards. The register has been previously described and validated for outcome classification [19]. The follow-up of all participants was performed until the occurrence of hiRF, emigration from Sweden or 31 December 2013. We defined hiRF as 585–586 according to the International Classification of Diseases, Revision 9 (ICD-9) and N18 and N19
according to ICD, revision 10. We additionally differentiated between hiRF as the main diagnosis, when registered as the first diagnosis in the patient record (90 cases), and hiRF as a contributing diagnosis, when the above-mentioned ICD codes were registered at a position other than the first (172 cases in total). For the analysis of incident hiRF, we excluded all participants with impaired kidney function at baseline (n = 6).

The CKD diagnoses were validated in a two-step quality process by two experienced specialists in nephrology who independently reviewed patient records and laboratory data in 100 randomly selected patients following the ICD-9 and ICD-10 codes for CKD. The validation showed that 94% of the patients had a correct diagnosis of CKD. Further details were published earlier [20].

Statistics
We analysed the baseline levels of p-KIM-1 per 1 standard deviation (SD) increment of the log value. In addition, we categorized the study sample according to p-KIM-1 levels into sex-specific equal quartiles. We tested the association between p-KIM-1 and baseline characteristics using a general linear model (GLM) for continuous variables adjusted for age and sex and a chi-square test for categorical variables. Furthermore, we tested the relationship between p-KIM-1 and the change in eGFR from the baseline to the follow-up examination, for which we calculated the annual change in eGFR by subtracting the baseline value from the follow-up value and dividing it by the follow-up time in years to account for the different lengths of follow-up.

Logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (CI) for incidence of CKD (eGFR at follow-up < 60 mL/min/1.73 m²). For the basic model we included age, sex and follow-up time as covariates. The net reclassification improvement (NRI) [21] was calculated using the nri STATA command for the package idi (http://personalpages.manchester.ac.uk/staff/mark.lunt). The receiver operating characteristics curves for incident CKD were generated and the areas under the curves (AUCs) of covariate-adjusted models with and without inclusion of p-KIM-1 were calculated using the roccomp command in STATA to compare predictive accuracy.

Cox proportional hazard (PH) regression was used to estimate the hazard ratio (HR) and 95% CI for the incidence of CKD. The PH assumption was tested using the Schoenfeld residuals (estat STATA command) and graphical (stphplot STATA command) assessment. The hazard function was graphically examined by plotting the Kaplan–Meier failure function (sts graph STATA command) according to quartiles of...
Table 1. Clinical characteristics of the MDCS-CC participants at baseline examination (1991–1996) according to quartiles of p-KIM-1

| Clinical characteristics | All | Q1 | Q2 | Q3 | Q4 | P-value |
|-------------------------|-----|----|----|----|----|---------|
| N                       | 4412| 1103| 1103| 1103| 1103|         |
| p-KIM-1, mean (range)   |    |    |    |    |    |         |
| Males                   |    |    |    |    |    |         |
| Age (years)             | 57.434 (5.945) | 55.040 (5.811) | 57.017 (5.836) | 57.945 (5.774) | 59.733 (5.370) | 0.006 |
| Height (cm)             | 168.813 (8.907) | 169.395 (8.722) | 169.059 (9.044) | 168.461 (8.921) | 168.109 (8.877) | <0.0001 |
| Weight (kg)             | 73.100 (13.368) | 72.213 (12.515) | 72.225 (13.066) | 73.378 (13.246) | 74.582 (14.446) | <0.0001 |
| BMI (kg/m²)             | 25.590 (3.912) | 25.038 (3.504) | 25.202 (3.797) | 25.806 (3.974) | 26.312 (4.214) | <0.0001 |
| Waist (cm)              | 83.230 (12.705) | 81.487 (11.828) | 82.121 (11.852) | 83.659 (12.902) | 85.651 (13.745) | <0.0001 |
| SBP (mmHg)              | 140.804 (18.820) | 135.410 (17.076) | 138.030 (17.458) | 142.550 (18.826) | 147.230 (19.640) | <0.0001 |
| DBP (mmHg)              | 86.653 (9.287) | 85.150 (8.495) | 85.150 (8.894) | 87.300 (9.488) | 89.020 (9.663) | <0.0001 |
| Fasting glucose (mmol/L)| 5.124 (1.273) | 4.892 (0.781) | 5.008 (0.961) | 5.132 (1.071) | 5.465 (1.902) | <0.0001 |
| HbA1c (%)               | 4.885 (0.705) | 4.683 (0.484) | 4.821 (0.568) | 4.885 (0.603) | 5.150 (0.976) | <0.0001 |
| Total cholesterol (mmol/L) | 6.144 (1.069) | 5.866 (1.018) | 6.041 (1.000) | 6.214 (1.055) | 6.454 (1.110) | <0.0001 |
| HDL (mmol/L)            | 1.394 (0.374) | 1.399 (0.357) | 1.398 (0.533) | 1.389 (0.374) | 1.389 (0.408) | 0.26 |
| LDL (mmol/L)            | 4.156 (0.976) | 3.948 (0.929) | 4.076 (0.914) | 4.216 (0.980) | 4.386 (1.024) | <0.0001 |
| TG (mmol/L)             | 1.307 (0.638) | 1.141 (0.535) | 1.246 (0.603) | 1.347 (0.621) | 1.493 (0.724) | <0.0001 |
| Cystatin C (mg/L)       | 0.775 (0.151) | 0.741 (0.119) | 0.761 (0.127) | 0.777 (0.135) | 0.820 (0.197) | <0.0001 |
| Plasma creatinine (µmol/L) | 84.483 (16.329) | 84.700 (14.804) | 83.270 (13.649) | 83.990 (15.443) | 85.970 (20.479) | 0.952 |
| eGFR² (mL/min/1.73 m²)  | 89.064 (13.568) | 91.624 (12.623) | 90.496 (13.015) | 88.823 (13.209) | 85.315 (14.524) | 0.0007 |
| AHT (%)                 | 16.7 | 11.2 | 13.8 | 17.1 | 24.8 | <0.001 |
| Current smoking (%)     | 25.9 | 20.4 | 22.8 | 26.6 | 33.9 | <0.0001 |

Data are shown as mean (SD).
P-value from a general linear regression adjusted for age and sex (continuous) or chi-square-test (categorical variables).

²log transformed.

The eGFR is based on CKD-EPI creatinine–cystatin C equation 2012 [18] (mL/min/1.73 m²).

RESULTS

Baseline characteristics

In total, 4412 participants were included in the study. Baseline height and p-KIM-1 were significantly associated with baseline eGFR, female sex, older age, use of AHT, current smoking and decreased height (Table 1). Furthermore, we observed positive associations between p-KIM-1 and several cardiometabolic characteristics and therefore additionally stepwise adjusted for all the tested baseline variables, yet none of them markedly changed the results (Supplementary data, Table S1).

Longitudinal changes

At the follow-up examination, the highest quartile of baseline p-KIM-1 was associated with a greater decline in total cholesterol and LDL (P < 0.001) but not with further anthropometric or clinical measurements. The mean decline in eGFR at follow-up was 23.92 mL/min/1.73 m² (SD 13.74). High baseline p-KIM-1 associated with a greater annual decline in eGFR (quartile 1 (Q1) –1.36 versus quartile 4 (Q4) –1.54 mL/min/1.73; P < 0.001) and an increase in plasma creatinine (P < 0.001) and plasma cystatin C (P < 0.001) after adjusting for age, sex, follow-up time and baseline levels of eGFR, creatinine or cystatin C, respectively. When the linear regression model was further adjusted for known risk factors of kidney dysfunction (BMI, SBP, fasting glucose, AHT and smoking), the higher baseline p-KIM-1 remained associated with a greater annual decline in eGFR (P-trend = 0.01) and an increase in plasma creatinine (P-trend = 0.01) and plasma cystatin C (P-trend = 0.01). (Table 2 and Figure 2A).

Incidence of CKD

CKD occurred in 882 participants, corresponding to 19.2 cases/1000 person-years throughout a follow-up time of 13.3–20.2 years. We observed a 70% increased incidence of CKD at the follow-up examination in participants with high levels (Q4) of p-KIM-1 at baseline compared with participants with low levels (Q1) in the basic model [OR 1.70 (95% CI 1.29–2.22)]. Although adding baseline eGFR, BMI, SBP, fasting glucose, AHT and smoking to the logistic regression model attenuated the risk increase, it clearly remained increased [OR 1.45 (95% CI 1.10–1.92)] (Figure 2B). When comparing a logistic regression model adjusted for known CKD risk factors (age, sex,
baseline levels of eGFR, SBP, BMI, fasting glucose, smoking status and use of AHT) and follow-up time to the same model additionally including p-KIM-1, we observed that including p-KIM-1 led to a marginal but significantly greater AUC (AUC 0.7872 versus AUC incl. KIM-1 0.7900; P = 0.05 for both). Among these patients, higher baseline p-KIM-1 associated with baseline levels of p-KIM-1 (waist, DBP, HbA1c, total cholesterol, LDL or triglycerides (TG)) would affect the observed association. The results remained similar (Supplementary data, Table S2).

In an attempt to relate the impact of p-KIM-1 on the CKD outcome in relation to the other risk factors at baseline, we analysed the risk increase per increment in 1 SD change of the included variables at baseline. As expected, low eGFR was by far the strongest predictor, with a 172% [OR 2.72 (95% CI 2.39–3.11)] increased risk of future CKD per 1 SD decrease at baseline. The risk increase by 1 SD increase of p-KIM-1 at baseline was 20% [OR 1.20 (95% CI 1.08–1.33)], which was similar to the risk increase by 1 SD increase of SBP [21%; OR 1.21 (95% CI 1.09–1.35)] and comparable to that of age [55%; OR 1.55 (95% CI 1.03–2.32)] (Table 3). Similarly, the relative impact on the annual change in eGFR was strongest for baseline eGFR (0.42 ml/ min/1.73 m² per 1 SD increase) followed by age (–0.19 ml/ min/1.73 m² per 1 SD increase), whereas the relative impact of p-KIM-1 was comparable to that of SBP, fasting glucose and BMI (–0.05 versus –0.06, –0.04 and –0.05 ml/min/1.73 m² per 1 SD increase, respectively) (Supplementary data, Table S3).

**Hospitalization due to impaired renal function**

During the mean follow-up time of 19.2 years (range 0–22.3), 90 participants were admitted to the hospital due to hiRF as the primary diagnosis. The sex-adjusted HR per 1 SD increase of p-KIM-1 was 1.94 (95% CI 1.63–2.30) and individuals within the highest quartile of baseline p-KIM-1 had a significantly higher risk for hiRF compared with participants within the lowest quartile [3.51 (95% CI 1.82–6.75)]. After adjusting for known risk factors (sex, baseline levels of eGFR, SBP, BMI, fasting glucose, smoking statutes and use of AHT), the HR for hiRF per 1 SD increase of p-KIM-1 remained significant [HR 1.43 (95% CI 1.18–1.74)], whereas the risk for individuals within the highest quartile of baseline p-KIM-1 was no longer significant compared with participants within the lowest quartile [HR 1.84 (95% CI 0.93–3.63)] (Table 4 and Figure 3).

However, when we included 82 additional cases with hiRF as the secondary diagnosis, the risk was attenuated but remained significant [HR Q4 1.78 (95% CI 1.08–2.94)] (Table 4 and Supplementary data, Figure S1). The results remained similar when we additionally adjusted the model for further covariates associated with baseline levels of p-KIM-1 (waist, DBP, HbA1c, total cholesterol, LDL or TG and all off these together) (Supplementary data, Tables S4 and S5).

**Change in eGFR among patients with diabetes at baseline**

In total, 76 participants had diabetes at baseline and their mean eGFR was 93.68 ml/min/1.73 m² (range 57.9–138.3). Among these patients, higher baseline p-KIM-1 associated with a greater decline in eGFR during the follow-up time (P = 0.0040) (Figure 4).

**DISCUSSION**

In our population-based cohort of middle-aged Swedish participants, we observed an association between higher baseline fasting p-KIM-1 and greater longitudinal decline of eGFR, higher incidence of CKD and hiRF after adjusting for known risk factors for kidney dysfunction. To our knowledge, this is the first population-based study investigating the relationship between
circulating p-KIM-1 and longitudinal kidney function in an apparently generally healthy population.

The gene encoding KIM-1 (HAVCR) is primarily expressed in the kidney cortex [22] and so far the majority of the previous human studies have investigated u-KIM-1 [3–6, 8–10]. The results of our study are in line with some previous human evidence reporting a relationship between p-KIM-1 and deterioration of kidney function in patients with T1D or early or advanced DKD [11–13], yet this study is the first to demonstrate that higher p-KIM-1 levels predict longitudinal deterioration of kidney function in a generally healthy population. Although only a limited number of individuals in our cohort had diabetes at baseline (N = 76), patients within the highest p-KIM-1 quartile had a significantly greater (65% increased) decline of eGFR compared with patients in the lowest quartile.

One earlier study measured both p-KIM-1 and u-KIM-1 in a cohort of T1D patients and observed that higher p-KIM-1 associated with an increased risk for early progression of renal decline independent of known clinical risk factors, including u-KIM-1, whereas this was not the case for u-KIM-1 [12]. Indeed, u-KIM-1 and p-KIM-1 are correlated (r = 0.43) [13], and it has been discussed that while u-KIM-1 reflects the acute production of protein that can vary widely over time, p-KIM-1 may reflect chronic ongoing injury [12]. The two markers may also mirror diverse aspects of proximal tubular damage: u-KIM-1 reflecting the extent of damage in the proximal tubule, while the movement of KIM-1 into the circulation may be facilitated by loss of cell polarity with injury, when KIM-1 may be released directly to the interstitium, or increased transepithelial permeability and disruption of the actin cytoskeletal architecture in renal microvascular endothelial cells [12, 13, 23–26].

A key factor of a biomarker is clinical applicability. When we added the p-KIM-1 baseline level to a model of commonly used risk factors, we were able to improve the classification for 9% of the participants into the correct risk direction using cNRI index analyses. However, improvement of the AUC was rather small and only marginally significant and therefore p-KIM-1 may only be moderately helpful in discrimination between individuals. Nevertheless, it needs to be taken into

![FIGURE 2: Association between baseline p-KIM-1 and decreased longitudinal kidney function and incidence of CKD in MDCS-CC.](image)

(a) Annual change in eGFR through quartiles of fasting p-KIM-1 at baseline among 2799 participants in the MDCS-CC during a mean follow-up time of 16.6 ± 1.5 years. Data are shown as mean (SE). The GLM was adjusted for age, sex and baseline eGFR. (b) Incidence of CKD at follow-up examination in relation to baseline levels of p-KIM-1 among 2765 participants in the MDCS-CC. High levels of p-KIM-1 associated with an increased incidence of CKD [OR 1.45 (95% CI 1.10–1.92)]. Data are shown as OR and 95% CI from the logistic regression model adjusted for age, sex, eGFR at baseline, SBP, AHT, BMI, glucose, smoking and follow-up time. The mean follow-up time was 16.6 ± 1.5 years. AHT, anti-hypertensive treatment; BMI, body mass index; eGFR, estimated glomerular filtration rate; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein; MDCS-CC, Malmö Diet and Cancer Study-Cardiovascular Cohort; SBP, systolic blood pressure; TG, triglycerides.

Table 3. Relative impact of clinical variables at baseline on the risk increase for CKD at follow-up examination in 2765 participants in the MDCS-CC in a multivariate logistic regression analysis

| Clinical characteristics | OR (95% CI) | P-value |
|--------------------------|------------|---------|
| Increase in age<sup>a</sup> | 1.55 (1.38–1.74) | <0.001 |
| Decrease in eGFR at baseline<sup>ab</sup> | 2.72 (2.39–3.11) | <0.001 |
| Increase in FU-time<sup>a</sup> | 1.38 (1.26–1.53) | <0.001 |
| Increase in SBP at baseline<sup>a</sup> | 1.21 (1.09–1.35) | <0.001 |
| Increase in fasting glucose at baseline<sup>a</sup> | 1.04 (0.90–1.19) | 0.622 |
| Increase in BMI at baseline<sup>a</sup> | 1.11 (1.00–1.23) | 0.052 |
| Increase in p-KIM-1 at baseline<sup>a</sup> | 1.20 (1.08–1.33) | 0.001 |
| Male | 1.05 (0.85–1.28) | 0.667 |
| Use of AHT | 1.48 (1.14–1.93) | 0.003 |
| Smoking status | | |
| Ex | 0.72 (0.56–0.93) | 0.013 |
| Current | 0.80 (0.62–1.02) | 0.066 |

<sup>a</sup>z-score transformed; the OR and 95% CI are given per 1 SD change in the respective variable.

<sup>b</sup>The eGFR is based on the CKD-EPI creatinine–cystatin C equation 2012 [18] (mL/min/1.73 m<sup>2</sup>).
consideration that receiver operating characteristic curve is predominantly used for diagnostic and not for prediction purposes. Moreover, both the predictive ability of the ‘traditional risk model’ and the strength of the new marker, as well as the potential correlation between them, impact on the effect of the change in AUC when p-KIM-1 was added to a risk model.

Furthermore, although cNRI was significantly improved by adding p-KIM-1, suggesting that it could be useful in reclassifying patients into correct risk directions, the relative impact (i.e. 1 SD change) of p-KIM-1 on the risk increase of CKD was rather modest compared with that of eGFR (20% versus 172% risk increase) and more comparable with that of SBP or age (21% and 55%, respectively), which may indicate a modest importance for p-KIM-1 as a clinical screening marker for risk of future CKD. However, p-KIM-1 may have clinical value regarding preventive regimes, but further studies are warranted in other large prospective population cohorts.

Our study has some limitations. One of the key limitations is the lack of data on albuminuria, which are required to determine CKD Stages 1 and 2 [29], and has in some studies shown to be of importance when investigating the association between KIM-1 levels and eGFR [8, 9]. However, in addition to studying CKD incidence, we analysed the overall change in eGFR by which we took into account the whole range of eGFRs in addition to the incidence of CKD. Second, although directly measuring GFR is hard to accomplish in a large cohort, using eGFR is a key limitation of our study. However, we used the most recent formula from the CKD-EPI, which takes into account both cystatin C as well as creatinine [18]. Third, only two measurements of creatinine and cystatin C were available in our cohort and more measurements would have been desirable according to the current Kidney Disease: Improving Global Outcomes 2012 guidelines [29]. Fourth, we used the cut-off for defining incident CKD as an eGFR of <60 mL/min/1.73 m² at the follow-up examination. Different views on how CKD should be classified exist, particularly concerning classification of the elderly [30], and using Stage 3A to define incident CKD could have led to an overdiagnosis, which may explain the high incidence rate of 31% in the MDCS-CC. However, p-KIM-1 may have clinical value regarding preventive regimes, but further studies are warranted in other large prospective population cohorts.
was comparably strong. Fifth, we were unable to quantify u-KIM-1. However, recent studies have reported that circulating KIM-1 correlates with u-KIM-1 ($r = 0.25–0.43$) [12, 13] and that p-KIM-1 may reflect both acute and chronic kidney injuries [13] and is associated with a rapid decline of kidney function in T1D patients, independent of u-KIM-1 [12]. Sixth, the number of participants with diabetes at baseline was low and therefore the observed greater impact of p-KIM-1 related to eGFR decline in patients with diabetes in our study needs to be further investigated. Lastly, given the observational design of our study, we are able to show longitudinal associations but cannot prove causality.

Nevertheless, our study also has some important strengths. To our knowledge, this is the first study investigating p-KIM-1 in a prospective population-based cohort of generally healthy participants, which expands the generalizability for using p-KIM-1 as a longitudinal marker for kidney function. Furthermore, our study had a long follow-up time, convincing results were obtained utilizing several endpoints and the results remained significant when adjusted for traditional risk factors.

In conclusion, our data from a prospective population-based study in generally healthy middle-aged participants suggest that elevated p-KIM-1 associates with a longitudinal decline of eGFR, increased incidence of CKD and hiRF. Therefore our study adds to the previous evidence highlighting the importance of p-KIM-1 as a potential predictive marker of kidney dysfunction in the general middle-aged population.

**SUPPLEMENTARY DATA**

Supplementary data are available at ndt online.

**FUNDING**

This study was supported by the European Research Council (Consolidator grant 649021, Orho-Melander), Swedish Research Council, Swedish Heart and Lung Foundation, Novo Nordic Foundation, Swedish Diabetes Foundation, and Pålsson Foundation and by equipment grants from the Knut and Alice Wallenberg Foundation, Region Skåne, Skåne University Hospital, Linneus Foundation for the Lund University Diabetes Center and Swedish Foundation for Strategic Research for IRC15-0067.

**AUTHORS’ CONTRIBUTIONS**

G.E., J.N., O.M. and M.O.-M. contributed to the research idea and study design. G.E., P.M.N., O.M. and M.O.-M. contributed to data acquisition. C.-A.S., G.E., P.A., A.C. and M.O.-M. contributed to data analysis/interpretation. C.-A.S. and M.O.-M. contributed to statistical analysis. G.E., A.C., M.O.-M. contributed to supervision or mentorship. Each author contributed important intellectual content during manuscript drafting for the overall work.
CONFLICT OF INTEREST STATEMENT

The authors declare that they have no other relevant financial interests related to this study. Preliminary results of this study were orally presented during the 52nd annual meeting of the European Association for the Study of Diabetes (EASD 2016: Oral Presentation 211).

(See related article by Arici. Kidney injury molecule-1: a successful quest for a predictive kidney disease marker? Nephrol Dial Transplant 2020; 35: 194–197)

REFERENCES

1. Ichimura T, Bonventre JV, Bailly V et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998; 273:4135–4142
2. Humphreys BD, Xu F, Sabbisetti V et al. Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 2013; 123: 4023–4035
3. Han WK, Bailly V, Abichandani R et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62: 237–244
4. Nielsen SE, Andersen S, Zdunek D et al. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 2011; 79: 1113–1118
5. Nielsen SE, Reinhard H, Zdunek D et al. Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract 2012; 97: 71–76
6. Vaidya VS, Niewczas MA, Ficociello LH et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase. Kidney Int 2011; 79: 464–470
7. Fufaa GD, Weil EJ, Nelson RG et al. Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia 2015; 58: 188–198
8. Panduru NM, Sandholm N, Forsblom C et al. Kidney injury molecule-1 and the loss of kidney function in diabetic nephropathy: a likely causal link in patients with type 1 diabetes. Diabetes Care 2015; 38: 1130–1137
9. Hsu CY, Xie D, Waiker SS et al. Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int 2017; 91: 196–203
10. Waiker SS, Sabbisetti V, Arnlov J et al. Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies. Nephrol Dial Transplant 2016; 31: 1460–1470
11. Coca SG, Nadkarni GN, Huang Y et al. Plasma biomarker and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol 2017; 28: 2786–2793
12. Nowak N, Skupien J, Niewczas MA et al. Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int 2016; 89: 459–467
13. Sabbisetti VS, Waiker SS, Antoine DJ et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type 1 diabetes. J Am Soc Nephrol 2014; 25: 2177–2186
14. Manjer J, Carlsson S, Elmsgaard H et al. The Malmo Diet and Cancer Study: representativeness, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 2001; 10: 489–499
15. Berglund G, Elmsgaard S, Jonason L et al. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993; 233: 45–51
16. Rosvall M, Persson M, Ostling G et al. Risk factors for the progression of carotid intima-media thickness over a 16-year follow-up period: the Malmo Diet and Cancer Study. Atherosclerosis 2015; 239: 615–621
17. Pero RW, Olsson A, Berglund G et al. The Malmo biological bank. J Intern Med 1993; 233: 63–67
18. Inker LA, Schmid CH, Tighiouart H et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20–29
19. Ludvigsson JF, Andersson E, Ekholm A et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450
20. Enhorning S, Christensson A, Melander O. Plasma copeptin as a predictor of kidney disease. Nephrol Dial Transplant 2018; 1–9. doi: 10.1093/ndt/gfy017
21. Pencina MJ, D’Agostino RB, D’Agostino RB Jr. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172
22. GTEx portal. Hepatitis A virus cellular receptor 1 gene expression. http://www.gtexportal.org/home/gene/HAVCR1 (29 May 2017, date last accessed)
23. Myers BD, Chui F, Hilberman M et al. Transtubular leakage of glomerular filtrate in human acute renal failure. Am J Physiol 1979; 237:F319–F325
24. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002; 62: 1539–1549
25. Sutton TA. Alteration of microvascular permeability in acute kidney injury. Microvasc Res 2009; 77: 4–7
26. Bonventre JV, Vaidya VS, Schmouder R et al. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010; 28: 436–440
27. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928–935
28. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2007; 54: 17–23
29. Levin A, Stevens PE. Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 2014; 85: 49–61
30. Glassock R, Delanaye P, El Nahas M. An age-calibrated classification of chronic kidney disease. JAMA 2015; 314: 559–560

Received: 6.5.2018; Editorial decision: 6.11.2018